Modulation of the acute phase response by altered expression of the IL-1 type 1 receptor or IL-1ra
- 1 April 2000
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
- Vol. 278 (4) , R824-R830
- https://doi.org/10.1152/ajpregu.2000.278.4.r824
Abstract
A complete understanding of the role for endogenously produced interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), and IL-1 receptor antagonist (IL-1ra) in the acute phase response to inflammation remains unknown. In the present studies, knockout mice lacking either a functional IL-1 type I receptor (IL-1RI−/−), a TNF type I receptor (TNFR-I−/−), or both IL-1 type I and TNF type I receptors (IL-1RI−/−/TNFR-I−/−) received a turpentine abscess. Additional mice deficient in IL-1ra protein (IL-1ra−/−) or overexpressing IL-1ra protein (IL-1ratg) were similarly treated. After a turpentine abscess, IL-1 receptor knockout mice exhibited an attenuated inflammatory response compared with wild-type or animals lacking a functional TNFR-I. Mice overexpressing IL-1ra also had an attenuated hepatic acute phase protein response, whereas IL-1ra knockout mice had a significantly greater hepatic acute phase response. We conclude that the inflammatory response to a turpentine abscess is the result of a balance between IL-1ra expression and IL-1 binding to its type I receptor. Endogenously produced IL-1ra plays a central role in mitigating the magnitude of the IL-1-mediated inflammatory response and, ultimately, the outcome to a turpentine abscess.Keywords
This publication has 26 references indexed in Scilit:
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid SecretionThe Journal of Experimental Medicine, 1998
- Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase responseCytokine, 1995
- The Interleukin-1 Receptor Antagonist (rhIL-1ra) Protects against Cerebral Infarction in a Rat Model of Hypoxia-IschemiaExperimental Neurology, 1994
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994
- Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6European Journal of Immunology, 1993
- Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.Journal of Clinical Investigation, 1992
- Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice.The Journal of Experimental Medicine, 1988
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.Journal of Clinical Investigation, 1988
- Isolation of alpha 1-acid glycoprotein from human plasma using high-performance liquid chromatographyAnalytical Biochemistry, 1985